Mohammad Shahrokh Esfahani: We aimed to study classic Hodgkin lymphoma using various noninvasive techniques applied to plasma ctDNA
Mohammad Shahrokh Esfahani, Instructor in Oncology at Stanford University, shared a LinkedIn post by Stanford Cancer Institute’s page, adding:
“Excited to see this work published in Nature. In this fantastic collaborative effort, we aimed to study classic Hodgkin lymphoma using various noninvasive techniques applied to plasma ctDNA of hundreds of patients.
Honored to have co-led this study with Stefan Alig, Andrea Garofalo, and Michael Yu Li.
Very nice Tweetorial by Ash Alizadeh.”
Quoting Stanford Cancer Institute’s post:
“A Stanford Medicine-led, international study of hundreds of samples from patients with Hodgkin lymphoma has shown that levels of tumor DNA circulating in their blood can identify who is responding well to treatment and others who are likely to experience a disease recurrence — potentially letting some patients who are predicted to have favorable outcomes forgo lengthy treatment.
SCI members Ash Alizadeh, MD, PhD, who is the Moghadam Family Professor, and Maximilian Diehn, MD, PhD, professor of radiation oncology and the Jack, Lulu, and Sam Willson Professor, are the senior authors of the research, which was published Dec. 11 in Nature.”
For the article click here.
For more details click here.
Source: Mohammad Shahrokh Esfahani /LinkedIn and Stanford Cancer Institute/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023